George Ayoub
CEO, QWIXEL Therapeutics
George received his B.S. in biochemistry from UCLA and received his M.B.A. from Pepperdine University. He co-founded and previously served as Chief Executive Officer and President of One Lambda, Inc., a transplant diagnostic company since 1984. In 2012, One Lambda was purchased by Thermo Fisher Scientific.
He spent ten years in the UCLA Tissue Typing Laboratory, where his studies focused on improving and developing methodology for Human Leukocyte Antigen (HLA) typing. While at UCLA, Ayoub authored and co-authored over 20 publications in the field of HLA research. His techniques described in these publications continue to be used to date in laboratories performing HLA typing for transplantation.
He serves as a member of the Board of Directors of Southern California Biomedical Council, a member on the UCLA TDG oversight committee, CEO of QWIXEL Therapeutics, a 2016 startup company with the focus on cancer treatment and a Board member of Nammi Therapeutics with focus on cancer treatment. George was the past Chairman of the UCLA Life Science Centennial Campaign Board.
George is also involved in various philanthropic projects. He continues to mentor startup companies in the medical field of diagnostics and therapeutics area. He received the prestigious Entrepreneur of the Year award from Ernst & Young in 2005, and he was also awarded the 2013 Maronite Civic Service and Lifetime Achievement award.